Newsroom

News
14 November 2016

Attention for PEDPZQ Consortium in German newspapers

On October 19, Merck KGaA, Darmstadt, Germany announced the donation to the World Health Organization (WHO) of the 500 millionth tablets to treat schistosomiasis in African countries.  In particular, members from Consortium partners, Merck KGaA (Darmstadt, Germany) and SCI (Schistosomiasis...

Read more
News
02 November 2016

From the Program Lead: Team effort makes the difference

Reviewing the different accomplishments in the last half year fulfils me with a true sense of pride for our team. It is the combined effort from all the Consortium partners that is making the difference. The Consortium team continues working with incredible dedication to make the highly needed...

Read more
News
01 November 2016

News Digest

The News Digest provides you with compelling stories about neglected diseases, published since the release of our previous newsletter in January 2016. 

Read more
News
01 November 2016

Schistosomiasis in Côte d’Ivoire: An interview with Prof. Dr. Eliézer K. N’GORAN

The Pediatric Praziquantel Consortium has initiated the Phase II clinical trial in Côte d’Ivoire, in Schistosoma mansoni-infected preschool-age children. Prof. Dr. Eliézer K. N’GORAN from the University Félix Houphouët-Boigny (Abidjan, Côte d’Ivoire) is the Principal Investigator of...

Read more
News
01 November 2016

Think and Talk Together/ Pensar e Falar Junto

Exciting days in Rio with the extended drug product subteam 

The year of the Rio de Janeiro Olympics also sees some important milestones for the Pediatric Praziquantel CMC team. The manufacturing process for orally disintegrating levo-Praziquantel tablets (L-PZQ ODTs) is now being...

Read more
News
01 November 2016

It’s all about access

The UK-based Schistosomiasis Control Initiative (SCI), part of Imperial College London, joined the Pediatric Praziquantel...

Read more
Events
17 October 2016

Consortium presenting at the ASTMH 65th Annual Meeting

In September, the Pediatric Praziquantel Consortium got acceptance of the abstract ’Outcome of two phase I relative bioavailability studies in healthy volunteers after administration of the new pediatric ODT formulations of racemate Praziquantel (rac-PZQ) and of the active enantiomer of...

Read more
Press release
12 October 2016

Schistosomiasis Control Initiative and Pediatric Praziquantel Consortium join forces in the fight against schistosomiasis

Goal is to make a child-friendly treatment for schistosomiasis accessible to children under six years of age in endemic countries

Read more
News
10 October 2016

Pediatric Praziquantel Consortium launches new website

Today, the Pediatric Praziquantel Consortium launches its new website. The website, with an up-to-date look & feel, is designed to help you learn more about the Consortium. We will be posting frequent updates, so check back regularly. 

...

Read more
Events
24 June 2016

Consortium on Stage at GHIT Annual Partners Meeting

On June 7, 2016, the GHIT Fund held its third Annual Partners Meeting to discuss the impact of the fund on the ground. The GHIT-funded PEDPZQ Consortium was invited to present its progress in clinical trials in African countries. 

Read more
News
16 June 2016

First patient dosed in Phase II clinical trial

Today, the Pediatric Praziquantel Consortium announced that the first patient in a Phase II pediatric clinical trial being conducted in the Ivory Coast has been dosed.

Read more
News
06 June 2016

Pediatric Praziquantel Consortium highlighted for rapid progress

The Pediatric Praziquantel Consortium was highlighted today in a press release issued by the Global Health Innovative Technology (GHIT) Fund.

Read more

Pages